Key clinical point: Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy after 3 months of DAPT.
Major finding: Ticagrelor monotherapy after 3 months of DAPT reduced the risk of clinically significant bleeding by 53%, compared with continued DAPT in high-risk patients after PCI for non-ST-elevation ACS.
Study details: This prespecified subgroup analysis of the TWILIGHT study included 4,614 patients who underwent PCI for non-ST-elevation ACS and 3 months of DAPT with ticagrelor and aspirin followed by double-blind randomization to a further year on the same regimen or to ticagrelor plus placebo.
Disclosures: The presenter reported receiving honoraria from AstraZeneca, the study sponsor.
Baber U. AHA late breaker.